Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity.
A bispecific F(ab')2 antibody conjugate (BAC) was constructed against the complement receptor CR3 of macrophages and variant CD44 (CD44v6) antigen of rat pancreatic adenocarcinoma cells to redirect macrophage-mediated tumor cytotoxicity. The Fab' fragments of monoclonal antibodies (mAb) 1.1ASML and OX42, recognizing the CD44v6 and the CR3 antigens respectively, were chemically coupled at the hinge region using 5,5'-dithiobis(2-nitrobenzoate). The BAC was characterized in vitro for its specific, dual binding capacity to CD44v6 and CR3 antigens. Although the monovalence of the BAC resulted in lower avidities to both the antigens as expected, it was still able to form stable cross-linkages between tumor cells and macrophages in culture leading to the formation of "clump-like" cell aggregates. The in vitro and in vivo tumor-targeting capacity of the BAC was compared with that of the parental antitumor mAb 1.1ASML, which mediates tumor killing by antibody-dependent cell cytotoxicity. These results showed that, even though the bivalent mAb 1.1ASML did not mediate stable cross-linking of target and effector cells, its Fc-receptor-mediated killing of tumor cells was more effective when compared to the BAC. Thus, this study strongly supports the hypothesis that firm persistent binding between effector and target cells per se is not as important as the choice of trigger molecule used for macrophage activation to redirect their tumor cytotoxic potential effectively.
Somasundaram
C
C
Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany.
Arch
R
R
Matzku
S
S
Zöller
M
M
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001667:Binding, Competitive; D003432:Cross-Linking Reagents / Q000737:chemistry; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D018960:Hyaluronan Receptors / Q000276:immunology*; D018796:Immunoconjugates / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D016219:Immunotherapy, Adoptive; D016177:Macrophage-1 Antigen / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D003432:Cross-Linking Reagents; D018960:Hyaluronan Receptors; D018796:Immunoconjugates; D016177:Macrophage-1 Antigen